Suppr超能文献

双位构象 G 蛋白偶联受体配体的合理设计:探索与展望。

Rational design of dualsteric GPCR ligands: quests and promise.

机构信息

Institute of Pharmacy, Rheinische Friedrich-Wilhelms-University, Bonn, Germany.

出版信息

Br J Pharmacol. 2010 Mar;159(5):997-1008. doi: 10.1111/j.1476-5381.2009.00601.x. Epub 2010 Feb 5.

Abstract

Dualsteric ligands represent a novel mode of targeting G protein-coupled receptors (GPCRs). These compounds attach simultaneously to both, the orthosteric transmitter binding site and an additional allosteric binding area of a receptor protein. This approach allows the exploitation of favourable characteristics of the orthosteric and the allosteric site by a single ligand molecule. The orthosteric interaction provides high affinity binding and activation of receptors. The allosteric interaction yields receptor subtype-selectivity and, in addition, may modulate both, efficacy and intracellular signalling pathway activation. Insight into the spatial arrangement of the orthosteric and the allosteric site is far advanced in the muscarinic acetylcholine receptor, and the design of dualsteric muscarinic agonists has now been accomplished. Using the muscarinic receptor as a paradigm, this review summarizes the way from suggestive evidence for an orthosteric/allosteric overlap binding to the rational design and experimental validation of dualsteric ligands. As allosteric interactions are increasingly described for GPCRs and as insight into the spatial geometry of ligand/GPCR-complexes is growing impressively, the rational design of dualsteric drugs is a promising new approach to achieve fine-tuned GPCR-modulation.

摘要

双功能配体代表了一种靶向 G 蛋白偶联受体 (GPCR) 的新方法。这些化合物同时与受体蛋白的正位配体结合位点和另外一个变构结合区域结合。这种方法允许通过单个配体分子利用正位和变构位点的有利特性。正位相互作用提供高亲和力的受体结合和激活。变构相互作用产生受体亚型选择性,此外,还可以调节效力和细胞内信号转导途径的激活。在毒蕈碱乙酰胆碱受体中,对正位和变构位点的空间排列的了解已经非常先进,并且已经完成了双功能毒蕈碱激动剂的设计。本文以毒蕈碱受体为例,综述了从正位/变构重叠结合的提示性证据到双功能配体的合理设计和实验验证的过程。随着越来越多的 GPCR 被描述为变构相互作用,以及对配体/GPCR 复合物的空间几何结构的了解令人印象深刻,合理设计双功能药物是实现精细 GPCR 调节的一种很有前途的新方法。

相似文献

1
Rational design of dualsteric GPCR ligands: quests and promise.双位构象 G 蛋白偶联受体配体的合理设计:探索与展望。
Br J Pharmacol. 2010 Mar;159(5):997-1008. doi: 10.1111/j.1476-5381.2009.00601.x. Epub 2010 Feb 5.
8
Allosteric modulators targeting CNS muscarinic receptors.靶向中枢神经系统毒蕈碱受体的变构调节剂。
Neuropharmacology. 2018 Jul 1;136(Pt C):427-437. doi: 10.1016/j.neuropharm.2017.09.024. Epub 2017 Sep 18.
9
Allosteric modulators of G-protein-coupled receptors.G蛋白偶联受体的变构调节剂
Curr Opin Pharmacol. 2003 Oct;3(5):551-6. doi: 10.1016/s1471-4892(03)00107-3.

引用本文的文献

3
[Not Available].[不可用]。
Acta Pharm Sin B. 2024 Jan;14(1):67-86. doi: 10.1016/j.apsb.2023.07.020. Epub 2023 Jul 21.
10
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.mTORC1 选择性抑制剂激活 4EBP1 并抑制肿瘤生长。
Nat Chem Biol. 2021 Oct;17(10):1065-1074. doi: 10.1038/s41589-021-00813-7. Epub 2021 Jun 24.

本文引用的文献

8
Conformational changes involved in G-protein-coupled-receptor activation.G蛋白偶联受体激活过程中涉及的构象变化。
Trends Pharmacol Sci. 2008 Dec;29(12):616-25. doi: 10.1016/j.tips.2008.08.006. Epub 2008 Oct 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验